Global Cannabidiol and Tetrahydrocannabinol Market Gain Huge Growth between 2018 to 2023 …

Cannabidiol & Tetrahydrocannabinol Market is poised to see considerable growth over the forecast period of 2018-2023. This report provides top and …

Cannabidiol & Tetrahydrocannabinol

Cannabidiol & Tetrahydrocannabinol Market is poised to see considerable growth over the forecast period of 2018-2023. This report provides top and emerging companies data based on geographical regions, and which further segmented into types and applications.

Global Cannabidiol & Tetrahydrocannabinol market covers major regions like North America, Europe and Asia-Pacific, South America, Middle East and Africa. Also, the report considers product scope, market overview, market opportunities, market risk, market driving force, sales, revenue, and price.

Request for Sample PDF of report at

The role of dealers and suppliers is highlighted in Cannabidiol & Tetrahydrocannabinol market research. The comprehensive study of Cannabidiol & Tetrahydrocannabinol market globally provides important facts in form of graphs, figures, and tables which will help the market players in making key business decisions.

Cannabidiol & Tetrahydrocannabinol Market by Top Manufacturers:

Elixinol, Isodiol, Medical Marijuana Inc., Canopy Growth Corporation, Aphria, Aurora Cannabis Inc., Cannoid

By Type

Food Grade, Pharmaceutical Grade

By Application

Food Industry, Pharmaceutical Industry,

Read Full Report at

Reasons for Buying Cannabidiol & TetrahydrocannabinolMarket Report: –

  • This report provides pin-point analysis for changing competitive dynamics of Cannabidiol & Tetrahydrocannabinol market.
  • It provides a forward-looking perspective on different factors driving or restraining Cannabidiol & Tetrahydrocannabinol market growth
  • It provides a six-year forecast assessed based on how the Cannabidiol & Tetrahydrocannabinol market is predicted to grow
  • It helps in understanding the key product segments and their future
  • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
  • It helps in making informed business decisions by having complete insights of Cannabidiol & Tetrahydrocannabinol market and by making in-depth analysis of Cannabidiol & Tetrahydrocannabinol market segments

Price of Report: $ 3500 (Single User License)

Purchase Report at

About Industry Research:

Industry Research is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.

Contact Us:

Name: Ajay More

Organization: Industry Reports

Phone: +1424 253 0807

Email : [email protected]

Related Posts:

  • No Related Posts

Is Marijuana Stock KushCo Holdings a Buy?

The best and worst performing of the four largest ones (by market cap), Cronos and Aurora Cannabis, respectively, are shown in the chart below.

Investor interest in marijuana stocks soared last year, thanks largely to several huge events, including cannabis becoming legal for recreational use in California (January) and Canada (October).

We’re going to examine KushCo Holdings(NASDAQOTH:KSHB) — which provides packaging solutions and other ancillary products and services to the legal cannabis industry — to see whether its stock is a buy.

Several marijuana products in various packaging, including buds, oil, and rolls.

Image source: Getty Images.

Stock performance: The short and longer term

One of the first things a potential investor in KushCo probably wants to know is how the stock has performed over the short and longer terms, including how it’s stacked up against other cannabis stocks.

A one-year loser

KushCo stock declined 18.6% over the one-year period through Friday, Jan. 18. By comparison, the S&P 500 (including dividends) edged down 2.7%.

The stocks of the Canadian marijuana growers are a mixed bag over this same period. The best and worst performing of the four largest ones (by market cap), Cronos and Aurora Cannabis, respectively, are shown in the chart below. (Tilray is actually the best performer of the larger players, but it’s only been traded in the U.S. since July.) Shares of ancillary cannabis companies Innovative Industrial Properties(NYSE:IIPR) and EnWave have performed wonderfully and solidly, respectively. Innovative Industrial Properties (IIP) is a San Diego-based, cannabis-focused real estate investment trust that’s profitable and pays a dividend yielding 2.6%; EnWave is a Canadian company that launched its dehydration technology into the cannabis industry last year.

KSHB Total Return Price Chart

Data by YCharts.

A winner since its IPO three years ago

Since its initial public offering in early January 2016, KushCo stock has surged 171% — more than four times the S&P 500’s 40.9% return. Aurora Cannabis has rocketed 1,370% higher over this period, while EnWave has gained 90.2%. (However, EnWave only became a “cannabis stock” last year.) Cronos and IIP aren’t shown because they have not traded in the U.S. (not traded, period, for IIP) for this entire period.

KSHB Total Return Price Chart

Data by YCharts.

KushCo’s business

KushCo Holdings, which is based in California, was founded in 2010 by Nick Kovacevich, the company’s CEO and chairman of the board, and Dallas Imbimbo, who serves on the board. The company started life as Kush Bottles and changed its name last year to reflect its expansion beyond its packaging roots. It’s very close to a pure play, with only its acquired creative-design business having clients outside the cannabis realm. In short, the company’s aim is to be a one-stop shop for customers.

KushCo has sales and distribution facilities across the U.S. and Canada, and opened an office in China last fall.

KushCo’s businesses include:

  • Kush Supply: The largest distributor in the U.S. of vaporizer products, packaging, supplies, and accessories to cannabis growers, processors, extractors, manufacturers, and retailers.
  • Kush Energy: Provider of pure hydrocarbon gases and solvents to the cannabis sector. These products are used to produce cannabis extracts, such as hemp-derived cannabidiol (CBD) oils. So this business should benefit from the December passage of the Farm Bill, which legalized hemp across the U.S. effective Jan. 1, 2019. (CBD is a nonpsychoactive chemical found in the cannabis plant that has been linked to various wellness benefits.)
  • The Hybrid Creative: A creative design agency providing services for cannabis and noncannabis brands.
  • Koleto: The company’s research and development arm.

KushCo’s leadership

As previously noted, Kovacevich leads the company. It’s generally a plus to have a founder running the business, since these folks know their companies intimately, and often have much skin in the game. Studies suggest that founder-led companies outperform in the stock market.

Kovacevich owned 11,035,000 KushCo shares, valued at about $59.9 million based on the closing price of $5.43 per share, as of his most recently reported transaction on Jan. 8. (This was a sale at prices ranging from $5.98 to $6.15 per share for a total of $1.21 million.) Kovacevich has a 13.8% stake in the company, with Imbimbo not far behind at about 13%.

KushCo’s financial performance

Like many in the sector, KushCo has revenue that’s been increasing rapidly, while its losses on both an operational and a net basis have been growing. The company is rapidly scaling up its business and investing to fuel long-term growth.

KSHB Revenue (TTM) Chart

Data by YCharts.

KushCo’s gross and operating margins have declined rather sharply since late 2017. Investors shouldn’t be overly concerned with operating margin at this point, given that the company is opening new facilities and otherwise spending to fuel long-term growth. (Operating margin will at least partly improve along with an improvement in gross margin.) But gross margin (total revenue minus cost of goods sold, divided by total revenue) is another matter.

In its fiscal Q1 earnings release, the company addressed this issue: “While we are confident in the Company’s upward trajectory, we acknowledge the impact that our dramatic growth has had on our gross margins, in particular, the utilization of air freight and additional cost incurring quality control measures at our receiving warehouse to meet demand. We have implemented a number of strategic operational initiatives that will drive our gross margins back toward 30% as we scale the business, with improvements in margins expected in the second half of fiscal 2019.”

KSHB Gross Profit Margin (Quarterly) Chart

Data by YCharts.

As to valuation, KushCo stock’s price-to-sales (P/S) ratio is 5.6, which is quite high in general, but reasonable relative to other cannabis stocks.

KSHB PS Ratio (TTM) Chart

Data by YCharts.

Investors need to keep an eye on liquidity and shareholder dilution. At the end of its most recently reported quarter, KushCo had cash and equivalents of just over $3 million and long-term debt of $7.2 million on its balance sheet. The company burned through $48 million in cash over the last year, financing its ramped-up spending through increasing its debt load and issuing significantly more shares of stock. (Over the last one and two years, the number of shares has increased about 27% and 62%, respectively.) Increasing the number of shares of stock has a dilutive effect on the ownership stakes of existing shareholders.

KSHB Cash and Equivalents (Quarterly) Chart

Data by YCharts.

Canopy Growth set to become the ‘global titan’ of cannabis: CIBC report

Canopy Growth Corp. in Smiths Falls is poised to dominate the global … And as the largest and most well-known cannabis company in the world, …

Canopy Growth Corp. in Smiths Falls is poised to dominate the global cannabis industry, a new report says.

The CIBC World Markets report compares the cannabis industry to both the gold rush and the development of the internet and the automobile. Only a few companies will live up to the “lofty expectations” of many and dominate the global market, said the report from the investment banking arm of the Canadian Imperial Bank of Commerce.

“We believe that Canopy Growth represents the industry’s best chance at a global titan.”

Canopy has billions in the bank, superior management, the potential to make breakthroughs with new medical products, and global aspirations, said the report. And as the largest and most well-known cannabis company in the world, Canopy also has a head start on global competitors.

“Investors rarely get to witness the birth of an industry,” said the report. While dozens of small and medium-size cannabis firms will earn moderate revenues, only a handful will dominate the global trade, the report predicts.

The report named Cronos Group as another likely winner. Cronos owns cannabis growing facilities in Ontario and British Columbia, and has international operations.

Canopy and Cronos stand out primarily because of their “best in class” management teams, said the report.

That’s a key factor in an industry in which stock prices ride a roller-coaster.

Prices fluctuate in response to news reports and regulatory changes. Consider Ontario’s rough start to the legalization of recreational cannabis on Oct. 17, with complaints of poor service and delayed deliveries at the online government store. Most Canadian cannabis growers lost 30 to 40 per cent of their company value in a week, the report noted.

On the other hand, even rumours of major players from other industries investing in cannabis can send stocks soaring.

Canopy had a market value of $19.8 billion at the end of the day Monday.

But such valuations matter less for cannabis companies than some other industries, the report said.

“The key element of any investor’s choice is management’s vision for the future, both for the industry as a whole and their own niche within the industry.”

Canopy’s Bruce Linton is probably the most famous cannabis CEO, said the report. That matters because of his familiarity to regulators and ability to negotiate with executives in other industries, it said.

Bruce Linton, founder, CEO and Chairman of Canopy Growth, travels from Ottawa to St. John’s, N.L. on the eve of legalization of pot in Canada to sell the first gram of legal pot from his Tweed store.Julie Oliver / Postmedia

The report said it’s not surprising that Canopy and Cronos have captured the two largest investments in the cannabis industry, from Big Alcohol and Big Tobacco.

Constellation Brands, a U.S. beer, wine and spirits company, poured $5.2 billion into Canopy to develop cannabis beverages. Tobacco giant Altria Group Inc. has a proposed investment in Cronos of $2.4 billion that will be voted on by shareholders next month.

Canopy, which began life as Tweed Marijuana in the old chocolate factory in Smiths Falls, has been the main ambassador for the cannabis industry, said the CIBC report.

The Hershey Canada Chocolate factory in 2007, shortly before closing.Mike Carroccetto / CNSPICS OTT

Canopy has been snapping up other companies at a rapid clip and expanding internationally.

It started by growing marijuana for medical patients and branched into recreational cannabis. Sometime this year, Canopy will unveil cannabis drinks, which officials promise will offer low-calorie, no hangover, healthier alternatives to alcohol.

However, the company still retains a strong focus on medical cannabis, where officials see global opportunity and the potential to replace pharmaceuticals and other products now used for sleep aids, pain treatment and mood therapy.

Canopy is also developing CBD products to treat anxiety in pets, another potentially huge market. (CBD is a non-psychoactive chemical found in cannabis and hemp.)

Staff work in a marijuana grow room at Canopy Growths Tweed facility in Smiths Falls, Ontario on Thursday, Aug. 23, 2018.Sean Kilpatrick / THE CANADIAN PRESS

Canopy Growth Corporation — by the numbers

2,500: Full-time employees

4.3 million: Square feet of Health Canada-licensed production space, spread over 13 facilities across the country that grow and process cannabis

15: Bricks-and-mortar Tweed or Tokyo Smoke stores the company operates in Newfoundland, Saskatchewan and Manitoba that sell recreational cannabis

$5.2 billion: Investment made into Canopy by Constellation Brands, the huge U.S. spirits, beer and wine company. Constellation Brands now owns 38 per cent of Canopy.

15: Countries in which Canopy has operations, partnerships, subsidiaries or business activities: Canada, U.S., Germany, United Kingdom, Colombia, Brazil, Australia, Chile, Denmark, Jamaica, Lesotho, Czech Republic, Spain, Poland and Peru.

$19.8 billion: Market value of Canopy Growth Corp. as of Monday

15: Approximate number of clinical trials Canopy has underway or planned to explore the potential medicinal benefits of cannabis

*sources: CIBC World Market, Canopy Growth Corp., Bloomberg


Ottawa’s ‘tired’ ByWard Market building requires more than $1M in short-term repairs

Ottawa is good. According to this public space guru, that’s the problem

Police arrest two men on firearm-related charges after collision

Related Posts:

  • No Related Posts

Aphria Inc. (TSX:APHA) Takes the Fight to Canopy Growth Corp (TSX:WEED)

Most investor focus was arguably on revenue and operating earnings growth as Aphria (TSX:APHA)(NYSE:APHA) released its Q2 2019 financial …

Most investor focus was arguably on revenue and operating earnings growth as Aphria(TSX:APHA)(NYSE:APHA) released its Q2 2019 financial results on January 11, but besides the noted takeaways from the earnings report, I find this little detail quite interesting.

The issue relates to a recently closed acquisition by Canopy Growth (TSX:WEED)(NYSE:CGC).

Recall that a smaller Aphria entered a strategic partnership with a “leading international consumer lifestyle brand” Tokyo Smoke back in September 2016 in a deal that was dubbed the “first ever cannabis licensing deal in Canada between a consumer brand and licensed medical cannabis producer” in a press release on September 7.

The deal allowed Aphria to ship Tokyo Smoke branded medical cannabis in Canada to registered patients, and the cannabis grower’s chief executive Vic Neufeld commented that “when cannabis is legalized for recreational use in Canada, a strong brand will be one of the key differentiators for patients and consumers, and we’re committed to working with Tokyo Smoke.”

The foresight was just great, as Tokyo Smoke later became a high-value, award-winning brand over the next two years, and it got acquired by cannabis grower DOJA Cannabis. The new entity re-branded itself to Hiku Brands. Aphria went on to make significant strategic investments in Hiku and signed another supply agreement with the fast-growing consumer brands outfit.

Then Canopy scooped Hiku in a deal announced in June last year.

Aphria realized a sizable return on its equity investments in Hiku, and the new investor in the cannabis retail company could be reasonably expected to cancel any supply agreements with the competition.

Here comes the challenge

Aphria accepts Canopy’s decision to terminate the Hiku supply agreement, but it refuses to let go of the Tokyo Smoke deal, as it strongly believes that Canopy has no capacity to terminate the earlier arrangement and “is pursuing all available legal options” to effectively block the “third party” from making such a move.

Is there any rationale to all this?

It’s evident that Aphria stood to significantly benefit from a distributorship agreement with Tokyo Smoke, especially as the recreational cannabis roll-out gains momentum. Distribution deals will become more valuable as new players increasingly bring new productive capacity online and a new scramble for market access takes hold as supply outstrips demand.

I’m no legal expert, but it appears like the 2016 deal had some clauses that allowed it to sustain regardless of material changes in ownership, and the company may have a serious intangible asset to protect in such an instance.

Tokyo Smoke is one of the four private players to obtain a master retail licence agreement to operate up to 10 adult-use cannabis outlets in Manitoba, and the brand was approved for distribution in Alberta. Such distribution licences are serious intangible assets whose value increases if provincial authorities limit the number of issuable licences, as recently happened in Alberta in November 2018.

That said, it’s reasonable to expect Canopy to terminate any distribution deals with close competitors as it invests in the Tokyo Smoke brand and spends a lot in marketing and branding efforts. The company wouldn’t be comfortable carrying on a formidable competitor’s brands and products on its platforms, even when the competitor talked to the previous owners of the acquired businesses first. It’s not in Canopy’s best interests to keep distributing a competitor’s product.

Aphria has cashed out of Hiku (and Tokyo Smoke in the process), hence the company may not expect to have its prior deals with Hiku to sustain under Canopy and the new “landlord” is right in attempting to cancel the disputed deal.

Actually, I don’t expect the legal battle to result in Aphria getting the agreement reinstated, but the company may receive some restitution for lost rights and economic benefits. The challenge is in the valuation of the disputed deal to determine compensation levels, especially if it covered a nascent recreational market as well as the United States market, which could soon come online as the legal landscape regime softens on cannabis regulation after the Farm Bill of 2018.

Foolish bottom line

The fresh legal battle between the two marijuana firms is just one of those interesting fights between close industry competitors as they work on maximizing the value of their investments and contracts.

Let’s watch how the legal system decides on this one.

You might be missing out on one of the biggest opportunities in Canadian investing history…

Marijuana was legalized across Canada on October 17th, and a little-known Canadian company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.

Besides making key partnerships with Facebook and Amazon, they’ve just made a game-changing deal with the Ontario government.

One grassroots Canadian company has already begun introducing this technology to the market – which is why legendary Canadian investor Iain Butler thinks they have a leg up on Amazon in this once-in-a-generation tech race.

This is the company we think you should strongly consider having in your portfolio if you want to position yourself wisely for the coming marijuana boom.

Learn More About This TSX Stock Now

Related Posts:

  • No Related Posts

Canopy Growth Corp. (CGC) aims to bring cannabis to the UK

21, 2019 /PRNewswire/ – Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) (“Canopy Growth” or the “Company”) is pleased to update key …
European Update: Spectrum Cannabis enters UK & Poland

High-quality medical cannabis available today in Polish pharmacies; UK presence positions Spectrum to lead in a key emerging market.

SMITHS FALLS, CANADA, OXFORD, UK, TORUŃ, POLAND, Jan. 21, 2019 /PRNewswire/ – Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) (“Canopy Growth” or the “Company”) is pleased to update key European progress in the UK and Poland where its medically-focused business Spectrum Cannabis continues to build a sophisticated, pan-European cannabis production and distribution network serving the needs of physicians and their patients throughout the continent.

United Kingdom

In the United Kingdom the Company has formed Spectrum Biomedical UK, a new company focused on providing access to cannabis-based medicinal products to UK patients with severe unmet clinical need.

Spectrum Biomedical UK was formed as a joint venture between Canada’s Canopy Growth and Oxford-based research-company Beckley Canopy Therapeutics to address a groundswell of patient need for high quality, standardised cannabis-based medicinal products in the UK. Under the British government’s new classification, which took effect November 1, specialist doctors in the UK can prescribe cannabis-based medicines to patients managing a wide range of symptoms – from chronic pain, chemotherapy-induced nausea and vomiting, to muscle spasticity for those with multiple sclerosis.

Following the launch, Spectrum Biomedical UK now has the opportunity to introduce Spectrum Cannabis medicinal cannabis products to UK patient groups and doctors. Spectrum UK will also engage in physician education to ensure doctors are exposed to the deep breadth of research showing the therapeutic benefits of cannabis. The combination of these actions will help build capacity within the UK’s healthcare sector, providing patients reliable access to Spectrum Cannabis products and information physicians can use to support them in their practice.

There is significant real-world and clinical evidence supporting the safety and effectiveness of cannabis-based medicinal products. However, due to the current regulations and lack of education about medicinal cannabis among clinicians in the UK, there remain considerable obstacles to patient access. Spectrum UK has the expertise and ambition to simplify the UK medicinal cannabis landscape and ensure access to cannabis-based medicinal products for patients with great clinical unmet need.

Dr. Mark Ware, Chief Medical Officer, Canopy Growth.


In addition to expanding its medicinal cannabis operations in the UK, Canopy Growth’s Toruń-based team, Spectrum Cannabis Polska, successfully completed its first import of medical cannabis after completing a rigorous regulatory approval process to have the product assessed and approved for sale.

In last week’s import, Spectrum Cannabis Polska received its high-THC whole flower product, Red No. 2. “This shipment is an important first step in a new European market towards building our pan-European operations,” says Dr. Pierre Debs, Managing Director, Canopy Growth Europe. “We continue to follow our overall plan of self-sufficiency in Europe to be able to best provide individuals with high-quality medical cannabis.”

Spectrum Cannabis Polska is a new entity and the fifth of its kind for the Company in European markets. According to the Polish Pharmaceutical Chamber, which represents about 15,000 pharmacies in Poland, it is estimated that up to 300,000 patients could qualify for medical cannabis treatment. The Company is committed to transforming healthcare in Europe by providing better access to medical cannabis treatments that have the potential to improve the lives of millions of patients.

Spectrum Cannabis: Medical Cannabis. Simplified.

About Spectrum Cannabis

Spectrum Cannabis, a wholly-owned subsidiary of Canopy Growth, is dedicated to simplifying medical cannabis for patients and healthcare practitioners. Spectrum Cannabis is an international medical business which interfaces with healthcare professionals and patients around the world. Founded in Canada, Spectrum Cannabis operates in Australia, South America, Africa and across Europe. Spectrum Cannabis products are available in a wide range of potencies and formats designed to simplify the dialogue around strength and dosage by applying a colour-coded Spectrum to categorize medical cannabis according to THC and CBD levels. Its product lineup includes whole flower cannabis, oils and new innovations such as Softgels. Through product simplification, easy dosing formats, and ongoing education of healthcare professionals, Spectrum is committed to improving the lives of medical cannabis patients around the globe.

About Canopy Growth Corporation

Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. Canopy Growth offers medically approved vaporizers through the Company’s subsidiary, Storz & Bickel GMbH & Co. KG. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time. The Company has operations in over a dozen countries across five continents.

The Company is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public’s understanding of cannabis, and through its wholly owned subsidiary, Canopy Health Innovations (“Canopy Health”), has devoted millions of dollars toward cutting edge, commercializable research and IP development. Canopy Growth works with the Beckley Foundation and has launched Beckley Canopy Therapeutics to research and develop clinically validated cannabis-based medicines, with a strong focus on intellectual property protection. Canopy Growth acquired assets of leading hemp research company, ebbu, Inc. (“ebbu”). Intellectual Property (“IP”) and R&D advancements achieved by ebbu’s team apply directly to Canopy Growth’s hemp and THC-rich cannabis genetic breeding program and its cannabis-infused beverage capabilities. Through partly owned subsidiary Canopy Rivers Corporation, the Company is providing resources and investment to new market entrants and building a portfolio of stable investments in the sector.

From our historic public listing on the Toronto Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. Canopy Growth has established partnerships with leading sector names including cannabis icon Snoop Dogg, breeding legends DNA Genetics and Green House seeds, Battelle, the world’s largest nonprofit research and development organization, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates ten licensed cannabis production sites with over 4.3 million square feet of production capacity, including over 500,000 square feet of GMP certified production space. The Company operates Tweed retail stores in Newfoundland and Manitoba and has entered into supply agreements with every Canadian province and territory. For more information visit

Original Press Release

Canopy Growth Corp. shares closed at $43.52 on Friday, up $0.75 (+1.75%). Year-to-date, CGC has gained 61.97%, versus a 6.62% rise in the benchmark S&P 500 index during the same period.

CGC currently has a POWR Rating of B (Buy), and is ranked #18 of 201 stocks in the Medical – Pharmaceuticals category.

This article is brought to you courtesy of Bloomberg.

Related Posts:

  • No Related Posts